Several studies have demonstrated that somatic mutations in the PI3K-Akt pathway could coordinate PTEN [67], mTOR [68], AR, MAPK, Wnt [69] and TGF-β signaling pathways [70] to play an important role in the tumorigenesis, progression, and treatment in prostate cancer. This evidence concerns the gene AR and prostate carcinoma.